These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 36785761)

  • 1. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
    Phillips NA; Rocktashel M; Merjanian L
    Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
    Azie N; Angulo D; Dehn B; Sobel JD
    Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
    Barnes KN; Yancey AM; Forinash AB
    Ann Pharmacother; 2023 Jan; 57(1):99-106. PubMed ID: 35502451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
    Nyirjesy P; Schwebke JR; Angulo DA; Harriott IA; Azie NE; Sobel JD
    Clin Infect Dis; 2022 Jul; 74(12):2129-2135. PubMed ID: 34555149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
    Kan S; Song N; Pang Q; Mei H; Zheng H; Li D; Cui F; Lv G; An R; Li P; Xiong Z; Fan S; Zhang M; Chen Y; Qiao Q; Liang X; Cui M; Li D; Liao Q; Li X; Liu W
    Mycopathologia; 2023 Apr; 188(1-2):99-109. PubMed ID: 36378354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
    Schwebke JR; Sobel R; Gersten JK; Sussman SA; Lederman SN; Jacobs MA; Chappell BT; Weinstein DL; Moffett AH; Azie NE; Angulo DA; Harriott IA; Borroto-Esoda K; Ghannoum MA; Nyirjesy P; Sobel JD
    Clin Infect Dis; 2022 Jun; 74(11):1979-1985. PubMed ID: 34467969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
    Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
    Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.
    Dixon GM; Lewis JS; Thompson GR
    Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):713-718. PubMed ID: 38957078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
    Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
    BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrexafungerp: A new triterpenoid antifungal.
    Sucher AJ; Thai A; Tran C; Mantena N; Noronha A; Chahine EB
    Am J Health Syst Pharm; 2022 Dec; 79(24):2208-2221. PubMed ID: 36083109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.
    Goje O; Sobel R; Nyirjesy P; Goldstein SR; Spitzer M; Faught B; Larson S; King T; Azie NE; Angulo D; Sobel JD
    J Womens Health (Larchmt); 2023 Feb; 32(2):178-186. PubMed ID: 36255448
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp.
    Grant LM; Orenstein R
    J Investig Med High Impact Case Rep; 2022; 10():23247096221123144. PubMed ID: 36059275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
    Adjapong G; Hale M; Garrill A
    Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
    Nyirjesy P; Brookhart C; Lazenby G; Schwebke J; Sobel JD
    Clin Infect Dis; 2022 Apr; 74(Suppl_2):S162-S168. PubMed ID: 35416967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
    Sobel R; Nyirjesy P; Ghannoum MA; Delchev DA; Azie NE; Angulo D; Harriott IA; Borroto-Esoda K; Sobel JD
    BJOG; 2022 Feb; 129(3):412-420. PubMed ID: 34676663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women.
    Gunther LS; Martins HP; Gimenes F; Abreu AL; Consolaro ME; Svidzinski TI
    Sao Paulo Med J; 2014; 132(2):116-20. PubMed ID: 24714993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of CDR1 and MDR1 efflux pump genes and fluconazole resistance are involved in recurrence in Candida albicans-induced vulvovaginal candidiasis.
    Esfahani A; Omran AN; Salehi Z; Shams-Ghahfarokhi M; Ghane M; Eybpoosh S; Razzaghi-Abyaneh M
    Diagn Microbiol Infect Dis; 2024 May; 109(1):116242. PubMed ID: 38452558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activity of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida species.
    Damke E; Tsuzuki JK; Cortez DA; Ferreira IC; Bertoni TA; Batista MR; Donati L; Svidzinski TI; Consolaro ME
    BMC Complement Altern Med; 2011 May; 11():35. PubMed ID: 21542936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy.
    Goswami D; Goswami R; Banerjee U; Dadhwal V; Miglani S; Lattif AA; Kochupillai N
    J Infect; 2006 Feb; 52(2):111-7. PubMed ID: 15908007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.